Table 1 Main characteristics of studies included in this meta-analysis
From: Expression of RABEX-5 and its clinical significance in prostate cancer
RABEX-5 mRNA expression | |||||
|---|---|---|---|---|---|
Variable | Group | High | Low | Total | P value |
Age | 0.052 | ||||
<70 | 55 (56.7%) | 42 (43.3%) | 97 | ||
≥70 | 35 (42.2%) | 48 (57.8%) | 83 | ||
Lymph node metastasis | 0.001 | ||||
Absence | 75 (46.0%) | 88(54.0%) | 163 | ||
Presence | 15 (88.2%) | 2 (11.8%) | 17 | ||
Surgical margin status | 0.578 | ||||
Absence | 82 (49.4%) | 84 (50.6%) | 166 | ||
Presence | 8 (57.1%) | 6 (42.9%) | 14 | ||
Seminal vesicle invasion | 0.851 | ||||
Absence | 73 (50.3%) | 72 (49.7%) | 145 | ||
Presence | 17 (48.6%) | 18 (51.4%) | 35 | ||
Clinical stage | 0.004 | ||||
T1 | 42 (40.8%) | 61 (59.2%) | 103 | ||
T2/T3 | 48 (62.3%) | 29 (37.7%) | 77 | ||
Preoperative PSA | < 0.001 | ||||
<4 | 1 (20%) | 4 (80%) | 5 | ||
4-10 | 20 (31.3%) | 44 (68.7%) | 64 | ||
>10 | 69 (62.2%) | 42 (37.9%) | 111 | ||
Gleason score | |||||
<7 | 29 (29.3%) | 70 (70.7%) | 99 | <0.001 | |
7 | 22 (64.7%) | 18 (35.3%) | 34 | ||
>7 | 39 (83.0%) | 8 (17.0%) | 47 | ||
Angiolymphatic invasion | 0.346 | ||||
Absence | 75 (51.7%) | 70 (48.3%) | 145 | ||
Presence | 15(42.9%) | 20 (57.1%) | 35 | ||
Biochemical recurrence | 0.009 | ||||
Absence | 56 (43.8%) | 72 (56.2%) | 128 | ||
Presence | 34 (65.4%) | 18 (34.6%) | 52 | ||